Genflow Biosciences PLC Announces Key SIRT6 Patent Application
-
French lawmakers divided over PM child abuse hearing
-
French chauffeur to face trial over alleged theft from UK minister
-
China's Alibaba posts annual revenue increase despite spending slump
-
Tracking the disinfo on Macron's 'cocaine use' in Ukraine
-
Fraser-Pryce admits family balance hard to maintain
-
Frankfurt extend coach Toppmoeller's deal until 2028
-
Germany's Commerzbank staff protest UniCredit takeover threat
-
To achieve peace, Syria must punish all crimes: rights lawyer
-
Gaza air strikes kill 94 as manhunt unfolds in West Bank
-
China warns Panama ports deal firms to 'proceed with caution'
-
China's Alibaba says annual revenue up six percent year-on-year
-
Russia, Ukraine trade insults ahead of Turkey peace talks
-
India and Pakistan trade accusations of nuclear arsenal mismanagement
-
EU accuses TikTok of violating digital rules over ads
-
Scotland's Ferguson ends injury nightmare with Bologna cup triumph
-
In Italian debut, 2027 America's Cup to be held in Naples
-
Stokes determined to 'dominate' on England return
-
Trump says 'getting close' to deal to avoid Iran military action
-
Vladimir Medinsky: Russia's history hawk leading talks with Kyiv
-
Haaland eyes FA Cup to save face after Man City's 'horrific' season
-
India says Pakistan nuclear arsenal should be under UN surveillance
-
Thai man arrested for smuggling baby orangutans
-
UK economy grows above forecasts, but tariffs threaten progress
-
Toxic algae killing marine life off Australian coast
-
Oil prices tumble on hopes for Iran nuclear deal
-
Russian delegation, without Putin, arrives in Istanbul for Ukraine talks
-
China first-quarter emissions fell despite rising power demand
-
Eurovision voting: when politics and kitsch converge
-
Eurovision: the 16 acts in second semifinal
-
Israel in Eurovision spotlight at second semifinal
-
Can cash handouts replace aid? Kenya offers some answers
-
Cuban cigarillo factory overwhelmed by burning demand overseas
-
Croatian town pays grandparents for childcare
-
Combs's ex Cassie to face intense defense questioning
-
Kinshasa deploys excavators against illegally built homes
-
All eyes on world's top trio as PGA Championship set to begin
-
Ukraine's Loznitsa warns of danger of despots at Cannes
-
'Unscientific' Japan megaquake rumours spook Hong Kong tourists
-
Timberwolves oust Warriors, Celtics down Knicks to stay alive
-
Dengue, chikungunya may soon be endemic in Europe: research
-
End of nuclear in Taiwan fans energy security fears
-
Reddit founder Ohanian buys stake in Chelsea women's team
-
Sun Yang to swim at China championships after doping ban
-
'I thought she'd survive': Story of slain Gaza photojournalist touches Cannes
-
Pandemic accord, tightened budget on menu at big WHO meet
-
Trump to close deal-making Gulf tour in UAE
-
Ex-All Black Mehrtens backing sleeping giant Beziers
-
Piastri in control, Ferrari floundering as F1 arrives in Europe
-
Premier League top-five hopefuls battle for Champions League riches
-
Under pressure from hard-right, Starmer takes cautious approach to EU 'reset'
NYSE - LSE
| CMSC | -0.43% | 21.965 | $ | |
| JRI | -0.86% | 12.77 | $ | |
| NGG | -0.15% | 67.43 | $ | |
| GSK | -0.36% | 36.22 | $ | |
| RIO | -0.39% | 62.03 | $ | |
| SCS | -1.61% | 10.54 | $ | |
| BTI | -0.35% | 40.55 | $ | |
| CMSD | -0.58% | 22.26 | $ | |
| BCE | -3.39% | 21.26 | $ | |
| BCC | -3.27% | 90.74 | $ | |
| RYCEF | -1.61% | 10.53 | $ | |
| BP | -0.66% | 30.36 | $ | |
| AZN | -2.25% | 66.23 | $ | |
| RELX | 1.24% | 53.06 | $ | |
| RBGPF | 100% | 63.81 | $ | |
| VOD | -0.22% | 9.04 | $ |
Genflow Biosciences PLC Announces Key SIRT6 Patent Application
LONDON, UNITED KINGDOM / ACCESS Newswire / May 15, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, announces that the Japanese Patent Office has advanced its SIRT6-related patent application (Application No. JP 2024515284) to the national examination phase.
The application, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," was originally filed on 13 May 2022 and is jointly owned by the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine. Genflow holds the exclusive license to this intellectual property.
The invention covers novel SIRT6 gene variants that play a central role in genomic stability, metabolic regulation, and healthy aging. These variants underpin Genflow's core therapeutic platform and represent a key part of its pipeline targeting age-related diseases.
The progression to national examination in Japan marks an important step in Genflow's strategy to establish broad international patent protection. Japan, with one of the world's most rapidly aging populations, is a priority market for longevity-related innovation.
Dr. Eric Leire, CEO of Genflow Biosciences, commented: "We are pleased to see continued momentum in the protection of our SIRT6 intellectual property. Japan represents a strategically important jurisdiction for Genflow, and advancing this patent application strengthens our global positioning as a leader in longevity gene therapy."
Genflow continues to progress its preclinical and clinical programs targeting age-related pathologies using the SIRT6 gene variants.
Contacts
Genflow Biosciences | Harbor Access | ||
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations | ||
+32-477-495-881 | +1 475 477 9401 | ||
Corporate Brokers | |||
Capital Plus Partners Ltd | |||
Jon Critchley, +44 0203 821 6168 | |||
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Expected to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
P.Mathewson--AMWN
